Completed

Retrospective Study to Evaluate the Safety of Sebryl® and / or Sebryl Plus® in the Treatment of Seborrheic Dermatitis and Psoriasis of the Scalp in Routine Medical Practice.

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected from past medical records and data - Retrospective
Who is being recruted

Dermatitis+4

+ Sebaceous Gland Diseases

+ Dermatitis, Seborrheic

+4 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: November 2021
See protocol details

Summary

Principal SponsorLaboratorios Silanes S.A. de C.V.
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: November 29, 2021

Actual date on which the first participant was enrolled.

The objective of this study is to evaluate the frequency and intensity of adverse events presented during treatment with Sebryl® and / or Sebryl Plus® for the management of seborrheic dermatitis and psoriasis of the scalp. The sample will be at convenience. The files of the patients who have received treatment with Sebryl® and / or Sebryl Plus® in the last 5 years (2016 to 2021) will be chosen. The researchers or the personnel designated by them will capture the information recorded by the treating physicians in the clinical file, sociodemographic, clinical and safety data that were presented after the prescription of Sebryl® and / or Sebryl Plus®.

Official TitleRetrospective Study to Evaluate the Safety of Sebryl® and / or Sebryl Plus® in the Treatment of Seborrheic Dermatitis and Psoriasis of the Scalp in Routine Medical Practice.
NCT05105139
Principal SponsorLaboratorios Silanes S.A. de C.V.
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

90 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

DermatitisSebaceous Gland DiseasesDermatitis, SeborrheicSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, EczematousSkin Diseases, Papulosquamous

Criteria

3 inclusion criteria required to participate
Any sex.
Treatment with Sebryl® and / or Sebryl Plus® documented, for at least 2 consultations.
That the patient has been questioned about possible adverse events
1 exclusion criteria prevent from participating
That the patient has used some other concomitant treatment for seborrheic dermatitis and psoriasis on the scalp.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Laboratorio Silanes, S.A. de C.V.

Mexico City, MexicoOpen Laboratorio Silanes, S.A. de C.V. in Google Maps
CompletedOne Study Center